Components of the RANK/RANKL/OPG System, IL-6, IL-8, IL-16, MMP-2, and Calcitonin in the Sera of Patients with Bone Tumors

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: is RANKL/RANK signalling really important?

(2011) J. Costa-Rodrigues et al.   CLINICAL & EXPERIMENTAL METASTASIS

Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis

(2011) W. C. Dougall   CLINICAL CANCER RESEARCH

Matrix Metalloproteinases 2, 7, 9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in the Sera of Patients with Bone Tumors

(2010) N. E. Kushlinsky et al.   BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE

Matrix Metalloproteinases 2, 7, and 9 and Tissue Inhibitor of Metalloproteinases-1 in Tumors and Serum of Patients with Ovarian Neoplasms

(2010) E. S. Gershtein et al.   BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE

Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration

(2010) Chin-Jung Hsu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma

(2010) Jun Ah Lee et al.   PEDIATRIC BLOOD & CANCER

Matrix metalloproteinases 2, 3, 13 and their type 2 tissue inhibitor in tumors and plasma of patients with colorectal cancer

(2008) E. S. Gershtein et al.   BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE